Literature DB >> 23979838

Parkinson's disease-associated DJ-1 mutations increase abnormal phosphorylation of tau protein through Akt/GSK-3β pathways.

Yangang Wang1, Weiping Liu, Xiaosheng He, Fei Zhou.   

Abstract

Hyperphosphorylated tau protein is the main component of neurofibrillary tangles found in Alzheimer's disease and Parkinson's disease (PD). Mutations in DJ-1 have been identified as the causative gene for Parkinson's disease 7 (PARK7)-linked PD. DJ-1L166P and DJ-1D149A, two types of DJ-1 mutations, are most commonly studied as the loss-of-function mutations responsible for early-onset familial PD. Whether mutations in DJ-1 result in tauopathy is as yet unknown. In this study, we found that the L166P and D149A mutant isoforms of DJ-1 associated with familial PD cause tau phosphorylation at Ser202, Ser262, and PHF1 (396/404) sites in neuroblastoma 2a cells. Glycogen synthase kinase (GSK)-3β phosphorylation at serine 9 (Ser9) decreases around 50 % in DJ-1L166P- or DJ-1D149A-transfected cells, while there is no change in total levels of GSK-3β. Our results also indicate that overexpression of DJ-1L166P or DJ-1D149A leads to a significant decrease in the level of phosphorylation of Akt at Thr308, which plays a critical role in phosphorylating GSK-3β at Ser9 and inhibiting its kinase activity. Importantly, insulin, the activator for Akt, effectively attenuates the reduced phosphorylation level of GSK-3β at Ser9 induced by DJ-1L166P. Neither the expression of cyclin-dependent kinase 5 nor the level of PP2A activity was found to have changed, suggesting that the familial PD-associated DJ-1L166P and DJ-1D149A mutations increase tau phosphorylation by increasing the activity of GSK-3β. Finally, we found that administration of lithium chloride, a well-known GSK-3β inhibitor, resulted in decreased levels of phosphorylated tau in DJ-1L166P-transfected cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23979838     DOI: 10.1007/s12031-013-0099-0

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  25 in total

1.  Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies.

Authors:  G Muntané; E Dalfó; A Martinez; I Ferrer
Journal:  Neuroscience       Date:  2008-02-05       Impact factor: 3.590

2.  Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes.

Authors:  Yan Yang; Delin Ma; Yuping Wang; Teng Jiang; Shuhong Hu; Muxun Zhang; Xuefeng Yu; Cheng-Xin Gong
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

3.  DJ-1, a novel regulator of the tumor suppressor PTEN.

Authors:  Raymond H Kim; Malte Peters; YingJu Jang; Wei Shi; Melania Pintilie; Graham C Fletcher; Carmela DeLuca; Jennifer Liepa; Lily Zhou; Bryan Snow; Richard C Binari; Armen S Manoukian; Mark R Bray; Fei-Fei Liu; Ming-Sound Tsao; Tak W Mak
Journal:  Cancer Cell       Date:  2005-03       Impact factor: 31.743

4.  DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathway.

Authors:  Hossein Aleyasin; Maxime W C Rousseaux; Paul C Marcogliese; Sarah J Hewitt; Isabella Irrcher; Alvin P Joselin; Mohammad Parsanejad; Raymond H Kim; Patrizia Rizzu; Steve M Callaghan; Ruth S Slack; Tak W Mak; David S Park
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-26       Impact factor: 11.205

5.  BAG1 restores formation of functional DJ-1 L166P dimers and DJ-1 chaperone activity.

Authors:  Sebastian Deeg; Mathias Gralle; Kamila Sroka; Mathias Bähr; Fred Silvester Wouters; Pawel Kermer
Journal:  J Cell Biol       Date:  2010-02-15       Impact factor: 10.539

Review 6.  Parkinson disease and driving: an evidence-based review.

Authors:  Alexander M Crizzle; Sherrilene Classen; Ergun Y Uc
Journal:  Neurology       Date:  2012-11-13       Impact factor: 9.910

7.  Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.

Authors:  Carles Gaig; Mario Ezquerra; Maria José Martí; Francesc Valldeoriola; Esteban Muñoz; Albert Lladó; Maria Jesús Rey; Adriana Cardozo; José Luis Molinuevo; Eduardo Tolosa
Journal:  J Neurol Sci       Date:  2008-03-19       Impact factor: 3.181

8.  A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization.

Authors:  Darren J Moore; Li Zhang; Ted M Dawson; Valina L Dawson
Journal:  J Neurochem       Date:  2003-12       Impact factor: 5.372

Review 9.  Role of serine/threonine protein phosphatase in Alzheimer's disease.

Authors:  Qing Tian; Jianzhi Wang
Journal:  Neurosignals       Date:  2002 Sep-Oct

10.  DJ-1 (PARK7) is associated with 3R and 4R tau neuronal and glial inclusions in neurodegenerative disorders.

Authors:  Ravindran Kumaran; Ann Kingsbury; Ian Coulter; Tammaryn Lashley; David Williams; Rohan de Silva; David Mann; Tamas Revesz; Andrew Lees; Rina Bandopadhyay
Journal:  Neurobiol Dis       Date:  2007-07-18       Impact factor: 5.996

View more
  10 in total

1.  Repurposing GLP-1 Receptor Agonists for Parkinson's Disease: Current Evidence and Future Opportunities.

Authors:  Daniella Balduino Victorino; Mariana Nejm; Marcia Guimarães-Marques; Fulvio Alexandre Scorza; Carla Alessandra Scorza
Journal:  Pharmaceut Med       Date:  2021-01-07

2.  Regulation of Signal Transduction by DJ-1.

Authors:  Stephanie E Oh; M Maral Mouradian
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

3.  Deficiency of Parkinson's Related Protein DJ-1 Alters Cdk5 Signalling and Induces Neuronal Death by Aberrant Cell Cycle Re-entry.

Authors:  María José López-Grueso; Carmen Alicia Padilla; José Antonio Bárcena; Raquel Requejo-Aguilar
Journal:  Cell Mol Neurobiol       Date:  2022-02-19       Impact factor: 5.046

4.  Coffee and caffeine potentiate the antiamyloidogenic activity of melatonin via inhibition of Aβ oligomerization and modulation of the Tau-mediated pathway in N2a/APP cells.

Authors:  Li-Fang Zhang; Zhi-Wei Zhou; Zhen-Hai Wang; Yan-Hui Du; Zhi-Xu He; Chuanhai Cao; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2014-12-24       Impact factor: 4.162

Review 5.  The Role of Insulin/IGF-1/PI3K/Akt/GSK3β Signaling in Parkinson's Disease Dementia.

Authors:  Liying Yang; Hongyan Wang; Lijun Liu; Anmu Xie
Journal:  Front Neurosci       Date:  2018-02-20       Impact factor: 4.677

6.  Effectiveness of Recombinant Human Growth Hormone Therapy for Children With Phelan-McDermid Syndrome: An Open-Label, Cross-Over, Preliminary Study.

Authors:  TianXiao Li; Ruijin Xie; Jinling Zhao; Hua Xu; Ying Cui; Chenyu Sun; Chunhong Wang; Yueying Liu
Journal:  Front Psychiatry       Date:  2022-02-16       Impact factor: 4.157

Review 7.  Tau protein modifications and interactions: their role in function and dysfunction.

Authors:  Anna Mietelska-Porowska; Urszula Wasik; Marcelina Goras; Anna Filipek; Grazyna Niewiadomska
Journal:  Int J Mol Sci       Date:  2014-03-18       Impact factor: 5.923

Review 8.  Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging.

Authors:  Mukesh K Pandey; Timothy R DeGrado
Journal:  Theranostics       Date:  2016-02-17       Impact factor: 11.556

Review 9.  The associations between Parkinson's disease and cancer: the plot thickens.

Authors:  Danielle D Feng; Waijiao Cai; Xiqun Chen
Journal:  Transl Neurodegener       Date:  2015-10-26       Impact factor: 8.014

10.  ROS networks: designs, aging, Parkinson's disease and precision therapies.

Authors:  Alexey N Kolodkin; Raju Prasad Sharma; Anna Maria Colangelo; Andrew Ignatenko; Francesca Martorana; Danyel Jennen; Jacco J Briedé; Nathan Brady; Matteo Barberis; Thierry D G A Mondeel; Michele Papa; Vikas Kumar; Bernhard Peters; Alexander Skupin; Lilia Alberghina; Rudi Balling; Hans V Westerhoff
Journal:  NPJ Syst Biol Appl       Date:  2020-10-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.